FDA/Cryogen Labeling Dispute Attracts Congressional Interest
This article was originally published in The Gray Sheet
Executive Summary
The House Commerce Committee has asked FDA Commissioner Jane Henney to review the agency's decision requiring Cryogen to submit a premarket approval application to expand the labeling of its First Option intrauterine cryosurgical probe to include specific references to endometrial ablation.
You may also be interested in...
CryoGen On Track For Second Quarter Endometrial Ablation PMA Submission
Cryogen plans to file data in support of a premarket approval application during the second quarter to expand labeling for the First Option intrauterine cryosurgical probe to include specific references to endometrial ablation as a treatment for dysfunctional uterine bleeding.
CryoGen On Track For Second Quarter Endometrial Ablation PMA Submission
Cryogen plans to file data in support of a premarket approval application during the second quarter to expand labeling for the First Option intrauterine cryosurgical probe to include specific references to endometrial ablation as a treatment for dysfunctional uterine bleeding.
CryoGen Anticipates Q2 2000 IDE Filing For Cardiac Cryoablation Device
CryoGen's transcatheter cryoablation device for the treatment of certain heart arrhythmias could enable physicians to treat ventricular tachycardia (VT), a condition not effectively addressed by radiofrequency (RF) ablation devices, the company claims.